Acadia Pharma (ACAD) Misses Q1 EPS by 10c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $20.59 -0.82%
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $115.5 million versus the consensus estimate of $121.92 million.
GUIDANCE:
Acadia Pharma sees FY2022 revenue of $510-560 million, versus the consensus of $540.7 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Oppenheimer Holdings (OPY) Reports Q3 EPS of $1.81
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
